Navigation Links
Abbott to Present at Citi Investment Research Global Health Care Conference
Date:5/7/2008

ABBOTT PARK, Ill., May 7 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) will present at the Citi Investment Research Global Health Care Conference on Thursday, May 22, 2008. Thomas C. Freyman, executive vice president, finance and chief financial officer, will make a presentation on the company at 7 a.m. Central time.

A live audio webcast of the presentation will be accessible through Abbott's Investor Relations Web site at http://www.abbottinvestor.com. An archived edition of the presentation will be available later that day.

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
2. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
3. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
4. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
5. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
6. Abbott Hosts Conference Call for First-Quarter Earnings
7. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
8. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
9. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
10. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
11. Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... DC (PRWEB) , ... May 26, 2016 , ... There ... National Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight ... dogs, 63 percent say grilling is their favorite way to cook a hot dog, ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... discovery of thousands of defective respirators, according to court documents and SEC filings. ... of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card will ... country. The nonprofit Hope For Heroes partnered with the leading provider of free ... military veterans, as well as police, firemen, and EMS professionals across the country, and ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: